Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What CAGR Is Anticipated for the Minimal Residual Disease Testing Market Through 2029?
In recent times, we have seen quick expansion in the minimal residual disease testing market size. The market is projected to rise from $1.59 billion in 2024 to $1.8 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.9% . The notable growth in the past can be traced back to progress in cancer research, increasing demand for treatment monitoring, robust clinical evidence, regulatory assistance, and enhancement in patient outcomes.
In the coming years, the market size for minimal residual disease testing is projected to experience swift growth. The market is forecasted to reach ” $2.91 billion in 2029 with a compound annual growth rate (CAGR) of 12.8%. This growth can be credited to the rise in cancer cases, advancements in treatments, trends of precision medicine, the drive for early diagnoses, and the integration of healthcare systems. Key trends for the forecasted period include the incorporation of liquid biopsy methods, emphasis on early detection of recurrence, expansion of MRD testing in clinical experimental trials, increasing acceptability in child oncology, and collaborations in research and development.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9970&type=smp
What Market Forces Are Driving The Minimal Residual Disease Testing Sector In 2025 And Beyond?
The rising incidence of cancer is anticipated to fuel the expansion of the minimal residual disease testing market. This medical condition occurs when a few cells in the body multiply uncontrollably and invade other parts of the body. Minimal residual disease testing is a highly sensitive technique used mainly for identifying stages of cancer; it enables the detection of cancer cells in the human body. This technique allows cancer patients to halt the disease at an early stage, thus stimulating the growth of the minimal residual disease testing market. For example, according to 2022 data from the American Cancer Society Inc., a nonprofit organization based in the US, about 1.9 million new cancer cases are expected to be identified, causing an estimated 609,360 cancer-associated deaths in the US in 2022. Consequently, the rising prevalence of cancer is a significant driving factor in the growth of the minimal residual disease testing market.
How Is The Global Minimal Residual Disease Testing Market Categorized By Segments?
The minimal residual disease testing market covered in this report is segmented –
1) By Test Type: DNA – Based Test, RNA- Based Test, Immunological Test
2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application
4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users
Subsegments:
1) By DNA-Based Test: Polymerase Chain Reaction (PCR) Tests, Next-Generation Sequencing (NGS), Digital PCR
2) By RNA-Based Test: Reverse Transcription PCR (RT-PCR), RNA Sequencing, Quantitative PCR (qPCR)
3) By Immunological Test: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry
Which Trends Are Redefining The Future Landscape Of The Minimal Residual Disease Testing Industry?
The introduction of innovative products is an emerging trend in the minimal residual disease testing market. Prominent companies in this market are constantly developing groundbreaking products to maintain their market dominance. For example, in 2022, Twist Bioscience, a company specialized in synthetic biology and genomics based in the United States, introduced the Twist MRD Panel. This product will significantly aid research and development in cancer screening for minimal residual disease (MRD). The Twist MRD Panel is a tailor-made panel of genes that identify extremely low levels of residual cancer cells in a patient’s bloodstream. Its design is highly adaptable and can be incorporated into a typical next-generation sequencing (NGS) process, which can discover minimal residual disease (MRD) within just five days.
Which Firms Are Considered Leaders In The Minimal Residual Disease Testing Market Space?
Major companies operating in the minimal residual disease testing market include Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton, Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Janssen Diagnostics LLC, Luminex Corporation, Menarini Silicon Biosystems S.p.A.
Get The Full Report Here:
What Role Do Regional Policies And Investments Play In Minimal Residual Disease Testing Market Expansion?
North America was the largest region in the minimal residual disease testing market in 2024. The regions covered in the minimal residual disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=9970&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model